Lupin, a pharmaceutical company, is set to acquire an established products portfolio in Europe and Canada from Sanofi for Rs 91 crore. The acquisition aims to expand Lupin’s presence in these regions and strengthen its product portfolio. This move will also contribute to Lupin’s growth strategy and market competitiveness. The company’s decision to invest in this portfolio demonstrates its commitment to enhancing its product offerings and meeting the healthcare needs of consumers in these markets. The acquisition reflects Lupin’s strategic approach to expanding its global presence and diversifying its product range.
Source link
Lupin to buy established products portfolio in Europe, Canada from Sanofi for Rs 91 crore
